JPMorgan Chase & Co. Issues Pessimistic Forecast for Grifols (NASDAQ:GRFS) Stock Price

Grifols (NASDAQ:GRFS) had its price target lowered by research analysts at JPMorgan Chase & Co. from $10.30 to $10.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 13.38% from the company’s previous close.

Other analysts also recently issued reports about the company. Zacks Research downgraded Grifols from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $8.82 on Monday. Grifols has a twelve month low of $6.19 and a twelve month high of $11.14. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. The firm has a fifty day simple moving average of $9.09 and a 200 day simple moving average of $9.42. The company has a market capitalization of $6.06 billion, a PE ratio of 46.42, a P/E/G ratio of 0.38 and a beta of 0.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Cetera Investment Advisers increased its stake in shares of Grifols by 16.1% in the 1st quarter. Cetera Investment Advisers now owns 35,254 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,900 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Grifols by 4.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 46,078 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 2,026 shares in the last quarter. Atlas Capital Advisors Inc. increased its holdings in Grifols by 3,948.1% in the 1st quarter. Atlas Capital Advisors Inc. now owns 30,118 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 29,374 shares during the last quarter. Groupe la Francaise purchased a new stake in Grifols in the 1st quarter worth $1,699,000. Finally, Vident Advisory LLC increased its holdings in shares of Grifols by 134.5% in the first quarter. Vident Advisory LLC now owns 69,564 shares of the biotechnology company’s stock worth $495,000 after purchasing an additional 39,902 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.